WayPoint Biomedical Receives Over-the-Counter FDA and CLIA Waived Clearance for Their Health Essist(R) Marijuana & Cocaine and

HUNTINGTON BEACH, Calif., Aug. 29  /PRNewswire-FirstCall/ -- WayPoint Biomedical Holdings, Inc. (Pink Sheets: WYPH) has received Food & Drug Administration (FDA) clearance for their two new over-the-counter (OTC) home use drug tests.  The Health Essist(R) Marijuana & Cocaine and Multi-Drug Cup (tests for 7 different drugs) tests will be entering the rapidly growing OTC Drugs-of-Abuse Testing Market -- estimated at over $30 million -- this fall, providing an easy-to-use, highly affordable, premium quality set of tests.

WayPoint Global Director of Sales & Marketing, Phil Richer, comments, "We are very excited with the tremendous news that our drugs-of-abuse tests are now cleared for OTC commercialization.  The Health Essist(R) line has been developed to allow the public to purchase affordable tests for use in the privacy of their own homes."  Mr. Richer adds, "Our home drug tests were developed to address the ever growing substance abuse issue; providing parents with additional tools to help combat this problem."

With over 99% accuracy, the urine based tests includes a feature that will allow the purchaser to anonymously submit their sample to an independent laboratory for outside confirmation, if so desired.

About WayPoint Biomedical:

WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (Pink Sheets: WYPH), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment.  The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition.  WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare.  The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science.  For more information on WayPoint Biomedical visit http://www.waypointbiomedical.com/ , http://www.drinkdetectiveusa.com/ .

Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance.  Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements.  In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political  conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

  Dennis Shepherd, 714-848-3200
  E-mail: 

  Investor Relations: The Steven Fox Group
  Steven Fox, 831-333-1452
  E-mail: 

DATASOURCE: WayPoint Biomedical, Inc.



CONTACT:  Dennis Shepherd of WayPoint Biomedical Holdings, Inc.,

[phone], ; or Investor Relations,

Steven Fox of The Steven Fox Group, [phone], , for

WayPoint Biomedical, Inc.



Web site:  http://www.waypointbiomedical.com/

http://www.drinkdetectiveusa.com/ 

Copyright